前苏联专利SU1528321A3 Method of producing indolysine derivatives or pharmaceutically acceptable salts thereof

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
New indolizine derivatives of general formula: …<IMAGE>… in which:… - B denotes an -S-, -SO- or -SO2- group,… - R denotes hydrogen, an alkyl, a cycloalkyl or a phenyl,… - each of R1 and R2, which are identical or different, denotes hydrogen, methyl, ethyl or halogen,… - A denotes an alkylene or a 2-hydroxypropylene,… - R3 denotes an alkyl or a radical of formula -Alk-R5 in which Alk denotes a single bond or an alkylene radical, R5 denotes a pyridine, phenyl, 2,3-methylenedioxyphenyl or 3,4-methylenedioxyphenyl radical or a phenyl group,… - R4 denotes hydrogen or an alkyl,… - or R3 and R4, when taken together, denote an alkylene or alkenylene radical.… Application: treatment of certain pathological syndromes of the cardiovascular system.
公开号:SU1528321A3
申请号:SU4203068
申请日:1987-08-11
公开日:1989-12-07
发明作者:Гюбен Жан；Шатлен Пьер；Декам Марсель；Низато Дино
申请人:Санофи (Фирма)；
IPC主号:

专利说明:

The invention relates to the preparation of new derivatives of indolysin of the general formula:
RI
Zh
0-A-;
l
de B -
R is lower alkyl linear
or branched, cyclohexyl, or unsubstituted phenyl; R and the same or different
hydrogen or methyl; A - linear or branched C-Su-alkylene; RJ is alkyl linear or branched or Alk-Rj-, where Alk is, alkylene or a simple bond, Rj is pyridyl or phenyl, unsubstituted or substituted by one or two alkoxy groups; R is hydrogen or alkyl;
or R and R4
- together with the nitrogen atom to which they are attached, form piperidinyl, imidazolyl, piperazinyl, 4-phenylpiperazinyl, 4-phenylpiperidini or 4-diphenylmethyl piperazinyl;
or B is -S-, with R being lower branched alkyl; A - linear C, -alkylene; R and R "are the same and denote linear alkyl or K is linear alkyl, and R is an Alk-Ry radical, where Alk is C2-alkylene, and Rj is phenyl substituted with two alkoxy groups,
or their pharmaceutically acceptable salts with cardiovascular activity "
The aim of the invention is to develop, on the basis of known methods, a method of obtaining new compounds with a wide range of pharmaceutical properties, namely the ability to inhibit calcium translocation, as well as bradycardiac ability, hypotensive
0
five
0
five
0
five
and antiadrenargic effects, with low toxicity.
Example 1, Preparation of 2-isopropyl-1- (3-di-n-butylamino-propyl) -4-hydroxybenzenesulfonyl-3-indolysine oxalate oxalate (CSR 3351, 3A)
a) 2-Isopropyl-1- (4-tosyloxy-benzenesulfonyl) -indolizin.
A mixture of 0.05 mol of 4-tosyloxyphenyl-B-picolylsulfone, 0.15 mol of 1-bromo-3-methyl-2-butano-ia and 0.05 mol of calcium carbonate in 100 ml of methyl ethyl ketone is kept at reflux for 22 hours. After this period of time, the reaction mixture is brought to ambient temperature and then filtered. The filtrate is thoroughly evaporated in vacuo in order to ward off excess bromoketone. The pasty residue is diluted in petrol ether, triturated and filtered. Thus, the last traces of brothketone are removed.
The residue obtained is treated with 200 ml of a 70/30 acetone / water mixture, acidified with several drops of hydrochloric acid, and then kept at reflux for several minutes. After cooling and filtering, the white solid is collected and can be recrystallized in acetone / water.
Thus, 2-isopropyl-2- (4-tosyloxybenzenesulfonyl) -indilisin is obtained at a yield of 70%, m.p. 180-183 C.
0
0
five
From the corresponding starting materials, using the proposed method, the following compounds are obtained:
2-methyl-1- (4-tosyloxybenzenesulfonyl) -INDolysin, t. Pl. 69 s (acetone);
2-ethyl-1- (4-toshoxtoxybenzene sulfonyl) -indolizin, m.p. 190 ° C (acetone);
2-n-propyl-1- (4-tosyloxybenzene-sulfonyl) -indolizin, m.p. 189 s (acetone);
2-ethyl-1- (3-methyl-4-tosyloxy-benzenesulfonyl) -indolizin, m.p. 164 C (methanol / chloroform);
2-n-butyl-1- (4-tosyloxybenzene-sulfonyl) -indolizin, m.p. 145 C. (acetone);
2-phenyl-1 - (4-tosyloxybenzene-sulfonyl) -indolizin, m.p. (dichloroethane);
168 seconds

2-phenyl-1- (A-tooeoyloxy-benzenesulfonyl) -indolizin, t. Gsh, 161 C (acetone);
2-cyclohexyl-1- (4-tooyloxybenzenesulfonyl) -indolizin, mp. 173- (acetone / water);
2-tert-butyl-1- (D-tosyloxybenzenesulfonyl) -indolizin, oily.
b) 2-Isopropyl-1- (4-hydroxybenzene-sulfonyl) -indolizin.
0.034 mol of 2-isopropyl-1- (4-tose-loxybenzenesulfonyl) -indolizine is poured into a mixture of 80 ml of water containing 0.34 mol of sodium hydroxide and 80 ml of ethanol, after which the reaction mixture is kept at reflux for 24 hours.
After cooling, the solution is diluted with 300 ml of water and then subjected to extraction with ethyl ether. After acidification of the aqueous phase, the formation of a precipitate is noted, which is dried and dried.
In this way, 2-isopropyl-1- (4-hydroxybenzenesulfonyl) -indolysin is obtained at a yield of 90%; 179-180 ° C (isopropanol / water 3/1).
From the corresponding starting materials, using the proposed method, the following compounds are obtained:
2-methyl-1- (4-hydroxybenzenesulfonyl) -indolizin, m.p. 177 C (methanol / water);
2-ethyl-1- (4-hydroxybenzenesulfonyl) indolysin, m.p. 204 ° C (ethyl acetate
2-n-propyl-1- (4-hydroxybenzenesulfonyl) -indolizin, so pl. 225 ° C (isopropanol);
2-ethyl-1- (3-methyl-4-hydroxybenzene-sulfonyl) -indolysis, t. Pl. 214 ° C (isopropanol);
2-n-butyl-1- (4-hydroxybenzenesulfonyl) -indolizin, so pl. 190 ° C (isopropanol);
2-phenyl-1- (4-hydroxybenzenesulfonyl) -indolizin, m.p. 234 ° C (methanol);
2-ethyl-1- (3,5-dimethyl-4-hydroxybenzenesulfonyl) -indolizin, m.p. 183 (isopropanol);
2-tert-butyl-1- (4-hydroxybenzenesulfonyl) -indolizin, so pl. 169 ° C (chloroform / petroleum ether);
2-cyclohexyl-1- (4-hydroxybenzenesulfonyl) -indolizin, so pl. 217 C (isopropanol / petroleum ether).
0

0 5
0
0
five
0
,
five
sixteen
c) Oxalate-2-isopropyl-1-C (3-di-n-butylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine.
0.015 mol of 1-chloro-3-di-n-butylamino propane and 0.018 mol of finely crushed potassium carbonate are added to 0.012 mol of 2-isopropyl-1- (4-hydroxybenzenesulfonyl) -indolizine in 100 ml of methyl ethyl ketone. Maintain the resulting mixture at reflux for 24 hours, after which it is brought. to ambient temperature. The inorganic salts are filtered off and the filtrate is evaporated in a vacuum pump. An oil is obtained, which is purified by chromatography on a dry aluminum hydroxide column.
Thus, the purified target compound in its basic form can be isolated in a crystalline state. An oxalate is formed from the resulting compound by adding a total amount of oxalic acid to a solution of the base dissolved in acetone.
In this way, oxalate 2-isopropyl-1- (3-di-n-butylaminopropyl) -4-hydroxybenzenesulfonylinsol is obtained at a yield of 26%; 133 C (isopropanol) (example 1).
From the corresponding starting materials, using the proposed method, the following compounds are obtained:
2-ethyl-1 - (3-piperidinopropyl) -4-oxy-5-benzosulfonyl-j-indolizine hydrochloride (SR 33528A) (example 2), mp. 183 ° C (acetone);
2-ethyl-1- (3-tert, -butylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine hydrochloride (SE 33511 A), t.p. 229-231 ° C (ethyl acetate / methanol) (Example 3);
2-methyl-1- (3-diethylaminopropyl) -4-hydroxybenzenesulfonyl-indolysine oxalate (SR 33520 L) (Example 4), mp. 153 ° C (dichloroethane / methanol);
2-methyl-1- (3-di-n-propylaminopropyl) -4-oxybenzenesulfonyl-J-indolizin (SR 33518) {example 5), t. Pl. 107-108 ° C (methanol);
2-methyl-1- (3-di-n-butyl-aminopropyl) -4-hydroxybenzenesulfonyl 1-indolysine oxalate (SR 331). (Example b), mp. 131 ° C (ethyl acetate);
2-ethyl- - (3-di-n-propylaminopropyl) -4-hydroxybenzenesulfonyl-1-indolizine hydrochloride (SR 33305 A) (example 7), mp. 192 C (acetone);
2-ethyl-1- (3-di-n-butylaminopropyl) -4-hydroxybenzenesulfonyl-J-indol-Zine hydrochloride (SR 33306 A) (Example 8), so pl. 153 C (acetone);
2-ETHYL-1- / 3-di-n-butylaminopropyl) -4-hydroxy-3-methylbenzenesulfonyl-indolizine hydrochloride (SR 33508 A) (Example 9), mp. 200-203 ° C (methyl ethyl ketone / methanol);
2-ETIHL-1- (3-di-n-butylaminopropyl) -4-oxy-3, 5-dimesh1benzenesulfonylZ-indolizine hydrochloride
(SR 33538 A) (example 10), t „pl. 136-137 ° C (ethyl acetate / methanol);
2-n-propyl-1- (3-di-n-butylaminopropyl) -4-hydroxy-benzene sulphonyl-indolizine oxalate (SR 33220 A) (example 11), mp 111 C (isopropanol);
2-n-butyl-1- (3-di-n-propylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine oxalate (SR 33507 A) (example 12), mp. 110-113 ° C (isopropa-iol);
2-n-butyl-1- (3-di-n-butylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine oxalate (SR 33504 A) (example 13), To pl. 85-87 with (ethyl acetate) 1
2-isopropyl-1- (3-dimethylaminopropyl) -4-ca (1-benzenesulfonyl-indolizine (SR 33517) (example 14), mp 90-92 C (simple diisopropyl simple diethyl
ether);
2-isopropyl-1 - (3-diethylamine propyl) -4-hydroxybenzole J-indolizine (SR 33516) (example 15), mp 90- (diisopropyl ether);
2-tert-butyl-1- (3-di-n-butyl-aminopropyl) -4-hydroxybenzenesulfos-1-indolysin (SR 33541) (example 16), t.p. 90-92 ° C (hexane);
oxalate-2-isopropyl-1- (3-di-n-propylaminopropyl) -4-hydroxybenzene sulfonate-indolizine (SR 33512 A) (example 17), so pl. 164-165 ° C (methyl ethyl ketone / methanol);
2-Phenyl-1- (3-di-n-butylamine Opropyl) -4-hydroxybenzenesulfonyl-indolizine hydrochloride (SR 33369 A) (Example 18), - t. square 158 ° C (acetone);
2-phenyl-1- (3-di-n- hydrochloride
butylaminopropyl) -4-hydroxy-3-methyl-benzenesulfonyl-indolizine (SR 33486A) (Example 19), mp. methanol);
2-ethyl-l- (N-methyl-3-N-by-thylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine oxalate (SR 33533 A) (Example 20), mp. (acetone);.
2-ethyl-1- (3-n-butylaminopropyl) -4-hydroxybenzenesulfonyl-indo oxalate: lezina, (SR 33534 A) (example 21), so pl. 141 ° C (acetone);
2-ethyl-1- (2-di-n-butylaminoethyl) -4-hydroxybenzenesulfonyl / -indolizine hydrochloride (SR 33547 A) (example 22), mp 153 C (ethyl acetate);
2-eth1-1- (4-di-n-butylaminobutyl) -4-hydroxybenzenesulfonyl-indoliein hemioxalate (SR 33548 A) (example 23), t. pl. 150 C (ethyl acetate);
2-Phenyl-1-C3-tert-butylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine hydrochloride (SR 33370.A) (Example 24), so pl. 228 ° C (acetone);
2-phenyl-1-C (3-tert-G) hydrochloride utilaminopropyl) -4-hydroxy-3-methylbenzenesulfonyl-indolizine (SR 33485 A) (example 2. i), so pl. (methanol);
2-ethyl-1- (3-di-n-pentylaminopropyl) -4-hydroxybenzenesulfonyl-iidolizine hydrochloride (SR 33550 A) (example 26), mp. 132-133 ° C (ethyl acetate / methanol); 2-ethyl-1- oxalate | 3- (3,4-dimethoxy-B-phenethylamine) -propyl-4-hydroxybenzenesulfonyl-indolysine (SR 33544 A) (Example 27), mp. 179 181 C (methanol);
2-ethyl-1-g 3-c-methyl-k- (3,4-di-methoxy-p-phenethyl) amine propyl-4-oxibenzenesulfonyl-indolizine; (SR 33549) (Example 28), t. Pl. 78-80 ° C (diisopropyl ether);
2-n-butyl-1-РЗ-tert-butylaminopropyl) -4-oxybenzolylsulfonyl i-indolysine oxalate (SR 33503 A) (Example 29), t. pl. 207-208 ° C (methanol);
2-IZOPROPSH1-1- {3-N-methyl-N- (3,4-dimethoxy-P) -phenethyl) -amine-propyl | -4-hydroxybenzenesulfonyl | -indolizin (SR 33557) (example 30), t. pl. 82-83 ° C (diisopropyl ether / dichloro methane); 1p
2-isopropyl-1- | (3-p-phenetsh1aminopropyl) -4-hydroxybenzenesulfonyl-indolizine hydrochloride (SR 33577 A) (Example 31), t. pl. 209-210 ° C (ethyl acetate / methanol);
2-Isopropyl-1- (3-benzylaminopropyl) -4-hydroxybenzenesulfonyl-1-indolysine hydrochloride (SR 33578 A) (prn
measures 32), so pl. 193-195 C (ethyl acetate / methanol);
2-isopropyl-1 - (3-And-phenylpiperazine propyl) -4-hydroxybenzenesulfonyl1-indolysine (SR 33579) (Example 33), To pl. 135-136 C (methanol / dichloromethane);
dioxalate 2-isopropyl-1- 3- (2-pyridylethylamine) -propyl-4-hydroxybenzenesulfonylA-indolizine (SR 33582 A (example 34), mp 154-156 ° C (methanol);
2-isopropyl-1- (4-phenylpiperidine) -propyl-4-hydroxybenzenesulfonyl 1 indolizin (SR 33583) (Example 35), To pl. 79-80 ° C (methanol);
2-isopropi.p-1 - (3-di-n-octylaminopropyl) -4-hydroxybenzenesulfonyl-indolysin (SR 33584) (Example 36),
m.p. 50 C (pasty substance);
2-isopropyl-1 - (3-di-n-pentylaminopropyl) -4-hydroxybenzenesulfonyl-indolizine hydrochloride (SR 33603 A) (example 37), so pl. 138 ° C (methylethyl ketone / ethyl ether 2: 1);
2-Ethyl-1-I (3- (l-imidazolyl) -propyl-4-hydroxybenzenesulfonyl-1-indolysin (SR 33590) (Example 38), mp 130-131 ° C (ethyl acetate / methanol / ethyl ether);
2-isopropyl-1- (4-di-n-butylaminobutyl) -4-hydroxybenzenesulfonyl-indolizine (SR 33606) (Example 39), To pl. 96 ° C (n-hexane);
2-ethyl-1- (5-di-n-butylaminopentyl) -4-acid-benzylphosphine-indol- (SR 33607) (example 40),
ZIN
m pl
89-90 0 (n-hexane-2-isopropyl-1-3-N-methyl-N- (3,4-dimethoxybenzyl) -amin-propyl-4-hydroxybenzenesulfonyl I -indolysin (SR 3361l) (Example 41), t. 96-100 ° C (diisopropyl ether / dichloromethane);
.-isopropyl- 1 - 11 4-and-methyl-N- (3,4-dimethoxy- | -phenethyl) -amine-butyl | -4-hydroxybenzenesulfonyl-indolidine (SR 33620) (example 42), That pl. 84-86 0 (hex.
2-isopropyl-J-3-Q 3,4-dimethoxibenzyl) -amin-propyl 1-4-1 cybenzenesulfonyl T-indolysin (SR 33621) (Example 43), so pl. 109-111 C (simple diisopropyl ether / dichloroethane)
2-isopropyl-1- hydrochloride | 3-3,4-dimethoxyapylin) propyl-4-hydroxybenzenesulfonyl-indolysine (SR 33624 A
0
r
0
five
(Example 44), t. pl. 200-203 C (metIt lenhlorid);
2-isopropyl-1- (3-K-n-butyl-H- (3,4-dimethoxy-p-phenethyl) -amine 1-propyl 1-4-hydroxybenzenesulfonyl 1 -indolysin (SR 33629 A) (Example 45 ), I t. Pl. 108-110 C (ethyl acetate / methanol);
2-isopropyl-1-11 acid oxalate 3H-c-methyl-H- (3-methoxy-β-phenylethyl) -amin-propyl-4-hydroxybenzenesulfonyl-D-indolizine (SR 33632 A) (example 46), Then square 111-113 ° C (ethyl ac tat / methanol);
2-isopropyl-1-K-methyl-K- (4-methoxy-B-phenethyl) -aminP-propylU-4-hydroxybenzenesulfonyl) -indolizine acid oxalate (SR 33638) (Example 47), mp . 140-144 ° C (ethyl acetate / methanol);
2-isopropyl-1-j 3- (4-diphenylmethylpipazine) -propylJ-4-oxybenzenesulfonyl -indolyzine (SR 33663 A) (Example 48), t.p. 170 ° C (methanol / dichloromethane);
2-isopropyl-1- | (3-dimethylamino-2-methyl-propyl) -4-oksibenzolisulfonyl-j-indolizin, t, pl. 131 C (Example 49);
2-cyclohexyl-1- (3-di-n-butyl-aminopropyl) -4-oxybet-13-sulfonyl-indolysin (SR 33641), to pl. 130-131 / methanol / (Example 50).
Example 51. Preparation of oxalate - (3-di-n-butylaminopropyl) -4-oxyphenylthioJ -2-isopropylindolizine (SR 33650 A).
a) Bro # 1d-1- (3-methyl-2-oxobutyl) -2- | (4-hydroxyphenyl) -thio-methyl-pyridinium.
A mixture of 0.02 mol 2-- is heated to boiling for 24 hours. f4-oxyphe-iyl) -thiol -MeTHj pyridine and 0.03 mol bromine methyl isopropyl ketone in 160 ml of acetone. After this period, the reaction mixture is brought to ambient temperature and the formation of a precipitate is noted, which increases with the addition of dry ethyl ether. This precipitate is filtered off, washed with dry ethyl ether and dried in vacuo.
0
0
five
0
Thus, 1- (3-methyl-2-oxobutyl) -2 - {(4-hydroxy-phenyl) -thio} -methyl 1-pyridinium bromide is obtained, which is used in crude form, Vyhol, 65%, m.p.
175 ° C.

c) 1- | (4-hydroxyphenyl) -thio -2-isopropylindolysin.
Pyridine bromide obtained at the preceding stage is dissolved in water and sodium bicarbonate taken in excess is added to this solution. The mixture is heated for 25 minutes at 90 ° C, then brought to ambient temperature. An oil is thus obtained, which is washed by decantation. This oil is dissolved in methanol, after which it is filtered, and then the methanol-containing solution is evaporated to dryness. Purification of the crude product obtained is carried out by chromatography on a silica column (eluant: dichloromethane / hexane 1/1).
Thus, 1- | (4-ociphenyl) -thio -2-isopropylindolysin is obtained at a yield of 90%, mp. 100 ° C.
c) Oxalate 1- (3-di-n-butylamine-propyl) -4-hydroxyphenylthio -2-isopropylindolizine.
To a solution of 0.01 mol of 1 - ((4-hydroxyphenyl) -TnoJ-2-isopropylindolysine in 80 ml of dimethyl sulfoxide, 5 g of anhydrous potassium carbonate and 0.015 mol of 1-chloro-di-n-but 11pamin-propane are added. Support the reaction the mixture is stirred for 24 hours and then washed with 500 ml of water. The solution is extracted with ethyl ether and the organic phase is washed with water. After drying on sodium sulfate, filtration and evaporation to dryness is carried out to obtain the desired product in crude form. dissolved in dry ethyl m and ether was added to the resulting solution of oxalic acid in ethyl ether protom.
Thus, 1- (3-di-p-butylaminopropyl) -4-hydroxy-phenyl-2-isopropylindolizine oxalate is obtained at a yield of 65%, mp. 118 C (ethanol / diisopropyl ether).
Using a similar technique, but based on the corresponding starting materials, the following compound is obtained:

oxalate 1- | 3-C-methyl N- (3,4-dimethoxy-P) -phenethyl) -lmin-propyl / - 4-hydroxyphenylthio j -2 and eopropylindo-lizine (SR 33651) (Example 52), 110 ° C.
square
0
five
0
five
8321
0
35
40
12
A pharmacological test is conducted to determine the cardiovascular activity of the compounds.
Calcium inhibitory effect
Inhibiting properties of calcium translocation on the membrane; The level of the proposed compounds is determined by measuring their resistance to contractile responses to depolarization, caused by potassium in an isolated rat aorta. It has been found that depolarization of the smooth muscle membrane with potassium makes the membrane permeable to extracellular calcium and causes a firm contraction.
Thus, measuring the inhibition of contractile response to depolarization using potassium or measuring the attenuation of tonic contraction to calcium depolarization gives an idea of the activity of the compound as an inhibitor of membrane permeability of calcium ions.
Use the following technique
In a male Wistar rat weighing approximately 300 g, the aorta is isolated, from which cavities are cut approximately 40 mm long and 3 mm wide.
These fragments are placed in a 25 ml container for isolated organs containing a solution of the modified Krabsbicarbonate, mK: NaCl 112; KCl 5; NaHCO, 25; , one; MgS04, 1.2; CaCl 2.5; glucose 11.5; distilled water up to 1000 ml, through which a stream of gas mixture (90% O / j - CO) is passed, maintain the temperature at 37 ° C. Combine the preparation with a force microsensor and record the contractile reaction after its enhancement.
, ++
Apply pressure of 2 g to the drug. The pressure was maintained for 60 minutes in a modified Krabs-bicarbonate solution on a Krabs-potassium solution containing, mM: NaCl 17; KCl 100; NaHCQ 25; KN, PO 1; MgSO. 1.2; glucose 11.5; distilled water up to 1000 ml. When the contractile response of the drug becomes reproducible, a predetermined amount of the test compound is introduced into the solution. After 60 minutes, a new spasm is provoked due to potassium depolarization.
13
The results obtained on the aorta being tested are expressed as a percentage of the maximum compressive effect before incubation with the test compound.
As examples, results were obtained using compounds taken as base, hydrochloride or oxalate.
Having established the ratio of activity between known and proposed compounds, the following results are obtained:
The ratio of activity
Connection (example 7) Connection S6,0
Connection (example 13) Connection A2,0
Connection (example 10) Connection B2,2
These results demonstrate the superiority of the proposed compounds over the corresponding, known.
Antiadrenergic i action.
The ability of the proposed compounds to reduce the increase in blood pressure caused by epinephrine (anti- effect), and the increase in the frequency of the heartbeat caused by isoprenaline (anti-oi effect) in a dog previously anesthetized with pentobarbital and given atropine are determined.
First of all, for each dog, the dose of epinephrine (between 3 and 10 mg / kg), which causes a reproducible increase in blood pressure of approximately 133-10 Pa, and the dose of isoprenaline (1-2 mg / kg), provoking a reproducible increase in the frequency of beating, are determined. hearts about 70 beats / min. Alternately, a dose of epinephrine and isoprenaline is administered every 10 minutes, after receiving two consecutive control responses, an amount of the test compound is administered intravenously.
Anti-wf effect ..
The percentage reduction in elevated blood pressure caused by the test compound is noted by comparing with the control value of increased arterial pressure (approximately 100 mm Hg).
The effect of anti- |).
ten
15
283211
Note the percentage of ycRae reduction in the frequency of the heartbeat caused by the test compound by comparison with control tachycardia (approximately 70 beats).
In both cases, the results of lowering blood pressure or heart rate are expressed as follows: + to reduce 50%; ++ to reduce 50%; for subtotal (reduction almost complete).
The results are shown in Table. four.
For known compounds, anti-adrenergic results are shown in Table. 5 o
Thus, the proposed compounds have a more significant anti-adrenergic activity and jb
Toxicity.
The acute toxicity of the compounds (l) is determined after the intravenous administration of these compounds.
The following results are obtained, expressed in the form of DL, which are compared with the benzoylin-dolisin derivative, in this case 2-ethyl-3G (3-di-n-butylaminopropyl) -4-oxyben 1 zoyl-indolysin or butoprozin:
20
25
thirty
five
0
five
Connection example
6 11
7
18 19 13 9
28 30 Butoprozin
Dl
5Q
MG / KG
31
28
26
35
60
31
55
32
140
23

权利要求:
Claims (1)
[1]
These results show that a comparison of the toxicity of butoprosis with the proposed compounds is favorable with respect to the latter. Invention Formula
The method of obtaining derivatives indizizina General formula
RI
R3.
0-a-n
,
R.
de
In R
R .. and R. And R. 151528321
-soj-;
linear or branched lower alkyl, cyclohexyl, or unsubstituted phenyl;
identical or different hydrogen or methyl; linear or branched C2 C5 alkylene; straight or branched alkyl or radical - Alk-R .., where Alk is alkylene or a simple bond, pyridyl or phenyl.
ten
R, 5 is not mixed or mixed with one or two alkoxy groups; Hydrogen or alkyl;
15
20
or R: and R
together with the nitrogen atom to which they are attached, form piperidinyl, imidazolyl, piperazinyl, 4-phenyl piperazinyl, 4-phenyl piperidinyl or 4-diphenylmethylene piperazinyl; or B is -S-, with R being lower branched alkyl; Cj-alkylene;
are the same and mean linear alkyl or R is linear alkyl, and R is radio A, and R
J6
Cal Alk-Rj, where Alk.- C-- alkylene, and Ry, mixed with two alkoxy groups,
or their pharmaceutically acceptable salts, characterized in that 1- (4-hydroxybenzenesulfonyl) 7 Indolysin of the general formula
MS
and R- have indicated
where b, r, r,
meanings
in the presence of a base, is reacted with a compound of the general formula
X-A-NC ;,
25
Rз
R /
X - A,
halogen:
Rg and
R have indicated signs
cheni
in a polar solvent at the boiling point of the latter, followed by extraction of the target product in free form or in the form of pharmaceutically acceptable salts.
f
S024Q-0- (CH2VAni
R h
18
HH3 -N (n-C4Hg) e
nineteen
CH H3 -N (n-C4H9) 5
Table 1
55.6 77.2
44
—SSNSSN), H
H
OSSN 3 -KN- -OCHN
29.8
nineteen
31
-CH (CH)
32
-CHCCHj)
n
1528321
20 Continued table. one
3 - NH-CH-CH H
31,8
3 --NH-CH X f /
19.4
21
IZfZIITZnrZZijZZI
33-CH (CHA), HH3-M
hg
34
N-Sn (sns) e H H 3 -NH-CH-CH -
35-CHCCHs) HH3
36-CH (CH3) g HH3 -N (n-C, H47) 4
38-CgHsНН3
D7-CHCCHg) HH3
44-CH (CH3) 2 HH3
43-CH (CH ,,) j HH3
42
ri
-CHCCHj), HH 4 -N- (CH2) 21.1
1528321
22 Continuation tabl, 1
57.6
N25, 0
93.7
85, 9
sc
N- (
OSSN NH-O OSSS
OCHN CH-CH - -OSNz
SNS9SNz
ri
17.9
78.9
9.7
N- (CH2) 21.1
31 -CH (CHi) 2 nn 3 --NH-CH-i-CH-i-J
/
32 -CH (CH3), 2 nn 3 - NH-CH; - (3
33 —CH (CH3) EN 3
BEHIND
N.
-sn (cn) 2 nn 3 -NH-CH -CH.35 -CH (CH3) 2 N H 3 -KG) nG
J
/
73.9
65.9
-NQN87, 0
N.
82.6
65.6
25
67
12345
zh I
37 —CH (CH) H H 3-NCn-CjH 77.8
39 -CH (CHj) 5 N H A-NCn-C Hg) 62.9,
, 40 -CjHs HH 5-NCn-C Hg), 87.9
41
Y vy
-CHCCHg) H H 3 -N-CH2 - OCH326.1
46-CH (CH9) HH3
-N- (CH2) 2-C CH3
47 -sn (ss) 2 H H 3 -N- (CH2)
44-CH (CH) HH
43-CHCCH,) HH3
42-CH (CH3) 2 HH4
45-CH (CHj) 2 HH3
27-SanDNN
28-C HS
HH3-30-CH (CH3) 2NH
Continued table. one
67
sns 9
Y vy
sns9 s
V
-N- (CH2) 2-C CH3
N- (CH2)
osnz
3 -NH- VoCH3
89.5
OCHN-NH-CHi 5 H3
СНЗО З
-N- (CH2) 2-O OCH3
"
n-C HgОСНз
-ShCHSN2) 2-O-OSSNz
at a dose
OCHN 3 (CH2) 2-O OCH3 81.6
one
sn.
3- OCHD
Zgosnz "5SNz Z
3 -N- (CH2)
A1-CH (CH5) j
HH3
A6-SNSSS)
HH3
47-CH (CH3) 2NH3
43-CHCCHj) HH3
42-SNSSNz), HH4
45-CNSSN) .НН3
(CH2) s-At
rVlrR N31-SNSSCH3), -N-Cn-CflHq),
II
52 -sn (sne), -N- (CH2) СНзО З
N-CHo-O-OCH-,
J
СНз0
N- (CH2) 2-O
SNZ LY- (CH2) 2-ONOSNz
70.9
78.1
86.5
88.7
. 78,8
pC NEOSNz
-lll- (CH2) 2-O-OCH3
80.7
table 2
69.2 81.2
29
Order 7519/58
Circulation 352
VNIIPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, Raushsk nab. 4/5
152832Г
30 Table 3
Subscription

类似技术:

公开号 | 公开日 | 专利标题

SU1528321A3|1989-12-07|Method of producing indolysine derivatives or pharmaceutically acceptable salts thereof

SU1597100A3|1990-09-30|Method of producing derivatives of benzimidazole

US4678783A|1987-07-07|Substituted isoquinolinesulfonyl compounds

US4634770A|1987-01-06|Isoquinolinesulfonamide derivatives

JP5400032B2|2014-01-29|Benzimidazole and pharmaceutical composition thereof

EP0390654B1|1994-11-09|Aminobenzenesulfonic acid derivative

EA010392B1|2008-08-29|Imidazole derivatives, the production thereof, and the use of the same as a medicament

US4029673A|1977-06-14|N-| substituted benzamides and derivatives thereof

US4354027A|1982-10-12|Triazoloquinoxalin-4-ones

US4847379A|1989-07-11|3,6-dihydro-1,5|-pyrimidinecarboxylic acid esters

US4868303A|1989-09-19|Bis-dioxopiperazine derivatives

US4647561A|1987-03-03|1,5-benzodiazepine compounds

SU1223843A3|1986-04-07|Method of producing 1-phenyl-2-aminocarbonylindole compounds or acid-additive salts thereof

KR20100132553A|2010-12-17|Novel n-|-acrylamides

US5013736A|1991-05-07|Azaazulene compounds which are useful as antiallergic and antiinflammatory agents

IE56652B1|1991-10-23|Antihypertensive n-piperazinylalkanoylanilides

RU2397159C2|2010-08-20|Method of producing |-acetylguanidine derivatives

US4510307A|1985-04-09|6-Quinazolinesulfonyl derivatives and process for preparation thereof

Oinuma et al.1991|Synthesis and biological evaluation of substituted benzenesulfonamides as novel potent membrane-bound phospholipase A2 inhibitors

US5053409A|1991-10-01|Aminobenzenesulfonic acid derivatives

EP0116628B1|1989-01-18|1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents

US4292431A|1981-09-29|Process for the production of hydroxymethylimidazoles

US5232922A|1993-08-03|Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates

FR2498183A1|1982-07-23|NOVEL GUANIDINOCYCLOHEXANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE THEREOF

RU2026293C1|1995-01-09|Method of synthesis of imidazole derivative

同族专利:

公开号 | 公开日

JP2547004B2|1996-10-23|

TNSN87021A1|1990-01-01|

HUT43604A|1987-11-30|

EP0235111B1|1991-04-10|

NO165344B|1990-10-22|

US4957925A|1990-09-18|

DK74087D0|1987-02-13|

AR245127A1|1993-12-30|

DK170403B1|1995-08-21|

PH24830A|1990-10-30|

KR870007931A|1987-09-23|

IL81358D0|1987-08-31|

SU1486064A3|1989-06-07|

US4994474A|1991-02-19|

OA08481A|1988-07-29|

DE3769174D1|1991-05-16|

PL153650B1|1991-05-31|

ZA87471B|1988-09-28|

NO870579L|1987-08-17|

BE1006666A4|1994-11-16|

FI870629A|1987-08-15|

SK97787A3|1998-12-02|

PL152609B1|1991-01-31|

MY101541A|1991-12-17|

FR2594438B1|1990-01-26|

MA20878A1|1987-10-01|

DD264436A5|1989-02-01|

CZ97787A3|1996-07-17|

AT62485T|1991-04-15|

IE870345L|1987-08-14|

IL81358A|1991-03-10|

NO165344C|1991-01-30|

DK74087A|1987-08-15|

YU46588A|1989-08-31|

HU196401B|1988-11-28|

US5147878A|1992-09-15|

PT84277A|1987-03-01|

FI84353B|1991-08-15|

EP0235111A1|1987-09-02|

YU21287A|1988-08-31|

JPS62192380A|1987-08-22|

SK279557B6|1998-12-02|

AU587525B2|1989-08-17|

US5017579A|1991-05-21|

PT84277B|1989-09-14|

FR2594438A1|1987-08-21|

ES2040276T3|1993-10-16|

FI84353C|1991-11-25|

IE59656B1|1994-03-09|

CA1310965C|1992-12-01|

NZ219274A|1989-04-26|

US5039700A|1991-08-13|

FI870629A0|1987-02-13|

CZ281209B6|1996-07-17|

NO870579D0|1987-02-13|

PL264078A1|1988-07-21|

AU6884687A|1987-08-20|

GR3001883T3|1992-11-23|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

DE1720033A1|1966-03-02|1971-05-19|Yoshitomi Pharmaceutical|New indole derivatives and processes for their preparation|

US3485835A|1968-04-10|1969-12-23|Haessle Ab|2-benzoyl-3-tertiaryamino alkoxy benzofuran derivatives|

IL32186A|1968-05-24|1974-10-22|Fisons Ltd|5-benzofuranyl compounds,their preparation,and physiologically active compositions containing them|

US3860609A|1969-05-27|1975-01-14|Novo Terapeutisk Labor As|3-aminoalkyloxyindoles|

US3859305A|1970-03-10|1975-01-07|Degussa|Indole aminoketones|

SE379196B|1971-06-24|1975-09-29|Sandoz Ag|

US3947470A|1974-06-20|1976-03-30|Smithkline Corporation|Substituted benzofurans and benzothiophenes|

US4013012A|1974-11-18|1977-03-22|Altus Corporation|Electronic safe arming and fuzing system|

FI61030C|1976-02-19|1982-05-10|Sanofi Sa|FRAMEWORK FOR THERAPEUTIC TREATMENT OF THERAPEUTIC NETWORK 2-SUBSTITUTES-1-ELLER 3-BENZOYL-INDOLIZERDERIVAT|

US4117128A|1976-08-03|1978-09-26|Smithkline Corporation|Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity|

FR2376145B1|1977-01-03|1980-03-28|Thea Therapeutiques Applic Sa|

GB1560006A|1977-08-18|1980-01-30|Laroche Navarron Sa|Benzoyl furan derivatives process for their preparation and therapeutic applications thereof|

US4128552A|1977-09-26|1978-12-05|Warner-Lambert Company|1-[4,4-Bisbutyl]-4-phenylthio-1,2,3,6-tetrahydropyridines and related sulfoxides and sulfones|

JPH0420916B2|1983-03-26|1992-04-07|Kyorin Seiyaku Kk|

US4654360A|1984-06-01|1987-03-31|Syntex Inc.|1,2,3-trisubstituted indoles for treatment of inflammation|

DE3426419A1|1984-07-18|1986-01-23|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW OXINDOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, AND INTERMEDIATE PRODUCTS|

US4675405A|1984-09-21|1987-06-23|American Home Products Corporation|Quinoline compounds as antiallergic and antithrombotic agents|

FR2584723B1|1985-07-09|1988-02-12|Adir|NOVEL 2,3-DIHYDRO-BENZOFURAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

DE3531658A1|1985-09-05|1987-03-12|Boehringer Mannheim Gmbh|HETEROCYCLICALLY SUBSTITUTED INDOLE, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|

FR2594438B1|1986-02-14|1990-01-26|Labaz Sanofi Nv|INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING SAME|

IL87181A|1987-08-07|1993-08-18|Sanofi Sa|Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them|

US4873259A|1987-06-10|1989-10-10|Abbott Laboratories|Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds|US5215988A|1986-02-14|1993-06-01|Sanofi|Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same|

IL87181A|1987-08-07|1993-08-18|Sanofi Sa|Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them|

US5182291A|1986-02-14|1993-01-26|Sanofi|Pyrozala-pyridyl aminoabkoxyphenol compounds|

FR2594438B1|1986-02-14|1990-01-26|Labaz Sanofi Nv|INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING SAME|

FR2633622B1|1988-07-04|1991-05-17|Sanofi Sa|SULFONYL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES|

CA2008985A1|1989-02-06|1990-08-06|Jean Gubin|Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same|

FR2642755B1|1989-02-07|1993-11-05|Sanofi|

FR2642756B1|1989-02-07|1994-03-04|Sanofi|CYCLOAMINOALKOXYPHENYL DERIVATIVES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL OR VETERINARY COMPOSITIONS CONTAINING THE SAME|

FR2665444B1|1990-08-06|1992-11-27|Sanofi Sa|AMINO-BENZOFURAN, BENZOTHIOPHENE OR INDOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM.|

US5118707A|1990-10-31|1992-06-02|The Procter & Gamble Company|Compositions for regulating skin wrinkles comprising a benzofuran derivative|

DE69224850T2|1991-08-09|1998-09-24|Nycomed Innovation Ab|USE OF PERMANENT FREE RADICALS FOR IMAGE GENERATION BY MEANS OF MAGNETIC RESONANCE|

FR2692578B1|1992-06-23|1995-06-30|Sanofi Elf|INDOLIZIN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF FOR THE PREPARATION OF AMINOALKOXYBENZENESULFONYL-INDOLIZINE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY.|

FR2692574B1|1992-06-23|1995-06-23|Sanofi Elf|4-HYDROXY BENZENETHIO DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF AMINOALKOXYBENZENESULFONYL DERIVATIVES.|

US5922773A|1992-12-04|1999-07-13|The Children's Medical Center Corp.|Glaucoma treatment|

FR2725133B1|1994-09-30|1996-12-20|Sanofi Sa|PHARMACEUTICAL COMPOSITION OF FANTOFARONE FOR ORAL ADMINISTRATION|

AU2103097A|1996-03-15|1997-10-10|Zeneca Limited|Cinnoline derivatives and use as medicine|

US6482854B1|1999-03-25|2002-11-19|Massachusetts Eye And Ear Infirmary|Glaucoma treatment|

US6699866B2|2001-04-17|2004-03-02|Sepracor Inc.|Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof|

NZ529333A|2001-04-27|2005-01-28|Eisai Co Ltd|Pyrazolo[1,5-a]pyridines and medicines containing the same|

FR2838123B1|2002-04-04|2005-06-10|Sanofi Synthelabo|NOVEL SUBSTITUTED INDOLOZIN-1,2,3 DERIVATIVES, SELECTIVE B-FGF INHIBITORS|

WO2004037800A1|2002-10-22|2004-05-06|Glaxo Group Limited|Aryloxyalkylamine derivates as h3 receptor ligands|

KR100699216B1|2003-01-31|2007-03-28|닛뽕소다 가부시키가이샤|Novel compounds capable of forming photoconvertible organic thin films and articles having organic thin films|

NZ617083A|2003-08-27|2015-04-24|Ophthotech Corp|Combination therapy for the treatment of ocular neovascular disorders|

US20070224278A1|2003-11-12|2007-09-27|Lyons Robert T|Low immunogenicity corticosteroid compositions|

US20050250737A1|2003-11-12|2005-11-10|Allergan, Inc.|Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods|

US20050101582A1|2003-11-12|2005-05-12|Allergan, Inc.|Compositions and methods for treating a posterior segment of an eye|

US20060141049A1|2003-11-12|2006-06-29|Allergan, Inc.|Triamcinolone compositions for intravitreal administration to treat ocular conditions|

ES2318453T3|2004-01-20|2009-05-01|Allergan, Inc.|COMPOSITIONS FOR LOCALIZED EYE THERAPY, WHICH INCLUDE, PREFERENCE, ACETONID TRIAMCINOLONE AND HIALURONIC ACID.|

US8673341B2|2004-04-30|2014-03-18|Allergan, Inc.|Intraocular pressure reduction with intracameral bimatoprost implants|

US20050244463A1|2004-04-30|2005-11-03|Allergan, Inc.|Sustained release intraocular implants and methods for treating ocular vasculopathies|

US8591885B2|2004-04-30|2013-11-26|Allergan, Inc.|Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems|

US20050244462A1|2004-04-30|2005-11-03|Allergan, Inc.|Devices and methods for treating a mammalian eye|

US20050244465A1|2004-04-30|2005-11-03|Allergan, Inc.|Drug delivery systems and methods for treatment of an eye|

US7799336B2|2004-04-30|2010-09-21|Allergan, Inc.|Hypotensive lipid-containing biodegradable intraocular implants and related methods|

US8119154B2|2004-04-30|2012-02-21|Allergan, Inc.|Sustained release intraocular implants and related methods|

US7993634B2|2004-04-30|2011-08-09|Allergan, Inc.|Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods|

US20050244466A1|2004-04-30|2005-11-03|Allergan, Inc.|Photodynamic therapy in conjunction with intraocular implants|

US7771742B2|2004-04-30|2010-08-10|Allergan, Inc.|Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods|

US8455656B2|2004-04-30|2013-06-04|Allergan, Inc.|Kinase inhibitors|

US9498457B2|2004-04-30|2016-11-22|Allergan, Inc.|Hypotensive prostamide-containing biodegradable intraocular implants and related implants|

US8147865B2|2004-04-30|2012-04-03|Allergan, Inc.|Steroid-containing sustained release intraocular implants and related methods|

US8425929B2|2004-04-30|2013-04-23|Allergan, Inc.|Sustained release intraocular implants and methods for preventing retinal dysfunction|

WO2005110374A1|2004-04-30|2005-11-24|Allergan, Inc.|Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component|

US20050244458A1|2004-04-30|2005-11-03|Allergan, Inc.|Sustained release intraocular implants and methods for treating ocular neuropathies|

US8722097B2|2004-04-30|2014-05-13|Allergan, Inc.|Oil-in-water method for making polymeric implants containing a hypotensive lipid|

US20050244461A1|2004-04-30|2005-11-03|Allergan, Inc.|Controlled release drug delivery systems and methods for treatment of an eye|

US20070059336A1|2004-04-30|2007-03-15|Allergan, Inc.|Anti-angiogenic sustained release intraocular implants and related methods|

US20050244471A1|2004-04-30|2005-11-03|Allergan, Inc.|Estradiol derivative and estratopone containing sustained release intraocular implants and related methods|

US20050244478A1|2004-04-30|2005-11-03|Allergan, Inc.|Anti-excititoxic sustained release intraocular implants and related methods|

US20060009498A1|2004-07-12|2006-01-12|Allergan, Inc.|Ophthalmic compositions and methods for treating ophthalmic conditions|

WO2006073938A2|2004-12-30|2006-07-13|East Carolina University|Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds|

AU2007223556A1|2006-03-01|2007-09-13|Roskamp Research Llc|Compounds for inhibiting beta-amyloid production|

US8969415B2|2006-12-01|2015-03-03|Allergan, Inc.|Intraocular drug delivery systems|

WO2008070875A2|2006-12-08|2008-06-12|Roskamp Research Llc|Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production|

US7911053B2|2007-04-19|2011-03-22|Marvell World Trade Ltd.|Semiconductor packaging with internal wiring bus|

UA101836C2|2008-04-15|2013-05-13|Эйсей Р Энд Д Менеджмент Ко., Лтд.|3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND|

AR078521A1|2009-10-08|2011-11-16|Eisai R&D Man Co Ltd|PIRAZOLOTIAZOL COMPOUND|

NZ716349A|2009-11-09|2017-07-28|Allergan Inc|Compositions and methods for stimulating hair growth|

RU2641021C2|2013-02-15|2018-01-17|Аллерган, Инк.|Implant for prolonged drug delivery|

CN108084186B|2016-11-16|2021-06-25|江苏新元素医药科技有限公司|URAT1 inhibitor and application thereof|

法律状态:
2006-02-20| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: PD4A |

优先权:

申请号 | 申请日 | 专利标题

FR8602045A|FR2594438B1|1986-02-14|1986-02-14|INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING SAME|LV920586A| LV5106A3|1986-02-14|1992-12-30|The method of obtaining indolizine derivatives or their pharmaceutically acceptable islands|

LTRP660A| LT2140B|1986-02-14|1993-06-17|THE BUDGET FOR RECOLLATION OF INDOLICIUM OR PHARMACEUTICALS SUITABLE SALTS|

[返回顶部]